Dear MAPS Supporters,
If you can make it to Los Angeles on Dec. 11th and 12th,
2010, we hope to see you at Catalysts,
our mini-conference with Stan Grof, M.D., Charlie Grob, M.D., Alicia Danforth,
Ph.D.s, Matt Baggott, Ph.D., Julie Holland, M.D., James Fadiman, Ph.D., Stephan
Beyer, Ph.D., Rick Doblin, Ph.D., and others. Tickets
are selling quickly, so we encourage you to get one before they sell out.
We have a great opportunity for anyone who likes to ski, snowboard,
sled, or hang out mountainside enjoying winter’s beauty. A generous MAPS
supporter has gifted MAPS a vacation rental at a ski chalet in Kirkwood,
California, a ski area 30 minutes from South Lake Tahoe. We’re passing this
good fortune on to you in the form of a raffle.
The vacation rental is valued at $800-$1200, and you can buy
raffle tickets for just $10, or buy
a dozen tickets for $100. We will randomly select the winner on Dec. 23,
2010. Of course, every ticket you buy supports psychedelic and marijuana
On Nov.1, our research combining MDMA with psychotherapy was
featured in the American Psychological Association’s major publication the Monitor on Psychology. The article, “Research
on Psychedelics Makes a Comeback,” was sent to every APA member, which
means tens of thousands of psychologists recently read about our promising
On Nov. 6, we hosted a marijuana summit in Denver, which was
featured in the New
York Times. On Nov. 7, we hosted an MDMA-psychotherapy workshop, followed
by a benefit event in Boulder, which was featured in the Boulder Weekly.
We’ve made considerable headway toward starting MDMA/PTSD studies in Canada,
Israel, and Jordan. Our study in the U.S. with veterans has enrolled its first
subject. Four subjects are already enrolled in our new ibogaine study. We
submitted our marijuana
for PTSD protocol to the FDA. Our clinical research team has been generating
numerous reports, and our Executive Director Rick Doblinhas
been globetrotting in order to oversee and assist in the aforementioned
As we move into the holiday season, we ask you to keep MAPS
in mind as you plan
your holiday charitable giving. We also want to remind you that MAPS
memberships make great gifts for friends and family.
Best wishes for a festive holiday season,
Randolph Hencken, M.A.
Director of Communication and Marketing, MAPS
What's happening this month at MAPS:
(Articles are below)
- MAPS Receives more than $100,000 in Donations from Seven Donors
- Mithoefer Presents Second Poster at ISTSS Conference
- US Veterans’ Study Begins Recruitment: First Subject Screened In!
- Video Archiving Begins for Swiss MDMA/PTSD Study
- Abbreviated Clinical Report About Israeli Study Completed
- Jordanian MDMA/PTSD Study Receives Full Approval From Hospital Ethics Committee
- MDMA Import License Submitted for Canadian Study
- Master Drug Tracking System Completed
- Marijuana/PTSD Study Gains Julie Holland, M.D., as Medical Monitor
- Ibogaine Study Enrolls Fourth Subject/International Conference
- International Journal of Drug Policy: Ayahuasca Track at Psychedelic Science Conference
- New Edition of Mavericks of the Mind by David Jay Brown
- MAPS Winter Raffle Contest: Ski House Rental Kirkwood, California (Tahoe area)
- Catalysts Conference and Related Events, Los Angeles, CA Dec. 10-12
We wish to acknowledge seven substantial donations we
recently received: $30,000 from the Riverstyx Foundation and $25,000 from an
anonymous family foundation for the US MDMA/PTSD study with veterans, $20,000
from John Gilmore, $10,000 from Ian Brown, $7705 from Anja Saunders for MDMA
research in general, $5000 from Adam Wiggins, and $5000 from Rene and Susan
Ruiz. We extend our sincere gratitude for these contributions.
On Nov. 5, 2010, at the International Society for Traumatic Stress
Studies annual conference in Montreal, Michael Mithoefer, M.D., presented findings,
in poster form, from the long-term follow portion of MAPS’ first completed
MDMA-assisted psychotherapy study. The poster showed overall therapeutic
results were sustained over time. Dr. Mithoefer presented the short-term
results from the study at the ISTSS conference in 2008. The new poster provides
a comprehensive overview of the study, including short-term and long-term data.
Dr. Mithoefer and others are preparing a paper about the results of the
long-term follow-up to the US pilot study for submission to a peer-reviewed
We are currently in the recruitment phase of our newest
U.S. study of MDMA-assisted psychotherapy for the treatment of posttraumatic
stress disorder (PTSD) exclusively with U.S. veterans from the Iraq,
Afghanistan and Vietnam wars. Nearly three-dozen veterans have inquired about
being subjects in the study, and one subject has passed the screening process.
Our research team is screening the other potential subjects to determine
eligibility. Pre-screening happens over the phone using an IRB-approved phone
script. When a subject passes
prescreening and continues to express interest in being a part of the study,
they are scheduled for an in-person medical and psychological assessment. One more person is scheduled for
screening during November and another is scheduled for screening in
December. Clinical Investigators Michael
Mithoefer, M.D., and Annie Mithoefer, B.S.N., are able to treat two or three
subjects a month. We are currently
on track for the study to move forward at a steady pace. We are actively
recruiting subjects from the Charleston area, if you know anyone who may be
MDMA/PTSD study collected video from nearly all of the sessions with
treatment subjects. We are now preparing a method to archive the videos for
future research purposes. This collection of video footage is a wealth of
information about therapy techniques and subjects’ responses to MDMA-assisted
psychotherapy. The archives will allow future researchers to do post-hoc
analysis on the videos from a third-party perspective. These researchers may or
may not be directly affiliated with MAPS. For example, this dataset could prove
invaluable to Ph.D. dissertations or other scientific studies. We are currently
investigating methods to duplicate and archive all this video data, which will
be time-consuming and presumably costly.
On Oct 14, 2010, Rick Doblin, Ph.D., met in Tel Aviv,
Israel, with Moshe Kotler, M.D., Principle Investigator of MAPS’ Israeli
MDMA/PTSD study. They discussed the abbreviated clinical report of the
results of the first five subjects, and the design of a new protocol. Dr.
Kotler and co-therapist Sergio Marchevsky, M.D., signed off on the report. It
will be submitted along with our new protocol application, which is still in
process, to the Israeli Ministry of Health. While in Tel Aviv and Jerusalem,
Rick met with psychologists who will
become co-therapists in the new study.
On October 20, Rick visited with Clinical Investigator
Nasser Shuriquie, M.D., at Al-Rashid Hospital to discuss our Jordanian MDMA/PTSD
study. The protocol was approved by the Al Rashid Institutional Review
Board (IRB) several days before the meeting and is being prepared for
submission to the Jordanian FDA. Rick
also met with Mona Abdulhamid Alnsour, Ph.D., co-therapist on the study who is
married to Dr. Nasser, in yet another husband/wife co-therapist team.
MAPS has hired the Antaea Medical
Services LTD to monitor the Jordanian study. On October 21, Rick met in Amman
with the primary monitor on the study Kamila Novak, the firm’s founder Mr.
Roussos, and their consultant Dr. Mohammad Rawashdeh (former Director of
the Jordanian FDA). They also discussed MAPS working with this firm on the
monitoring of our Israeli study.
On October 22, Rick’s last meeting in Amman was with two
State Department officials, both physicians, working at the U.S. Embassy in
Amman. The officials had previously visited Al-Rashid Hospital as part of their
Crisis Response evaluation work. There they had been told about MAPS’
sponsorship of the MDMA/PTSD study and had expressed an interest in meeting Rick.
The meeting got off to a great start when one of the officials recalled having been
in contact with Rick about ten years prior. Rick had contacted the Center for
the Treatment of Torture, in Minneapolis, Minnesota, to see if they would be
interested in a grant to study MDMA-assisted psychotherapy for PTSD. The
Embassy official worked at the Center at that time, but the Center wasn’t in a
position to conduct a clinical study. Ten years later, the Embassy official expressed
appreciation for Rick’s dedication to develop MDMA/PTSD research including the
Jordanian study. The meeting concluded with a discussion about MAPS’ U.S. MDMA/PTSD
study with veterans. The two officials acknowledged the need for new treatments
for PTSD and were sympathetic with MAPS’ Jordanian MDMA/PTSD project and U.S.
study with veterans.
On Nov. 1, 2010, Pharmacist Colin Holyk from Kerrisdale
Pharmacy resubmitted his application for a “licensed dealer permit” to Health
Canada in order to import MDMA for our Canadian
MDMA/PTSD study. The application was originally submitted in September
2009. It took Health Canada nine months to respond with several questions about
what activities the pharmacist would be conducting in order to be a licensed
dealer. It took our team some time to clarify the Canadian regulations, after which
we resubmitted the application. We look forward to Health Canada’s response,
and will do whatever is required in order to start this long anticipated study.
MAPS’ clinical research team has completed creating a master
drug tracking system for all MAPS’ MDMA studies. This database keeps records
about manufacturing, shipping, quality control, and analysis of the drugs over
years. We now have a central method of drug accountability to review at the
conclusion of a MDMA trial, which gives a comprehensive assessment of what
happened to the MDMA from start to finish. Our records go back to 2003 when the
first MDMA was shipped for our pilot study in Charleston, S.C.
Julie Holland, M.D., has reviewed the protocol and agreed to
be the medical monitor for our newest study of
marijuana as a treatment for PTSD. The protocol
was submitted to the FDA on Nov. 12, 2010, and on Nov. 17, 2010, MAPS
received a new Investigational
New Drug number for marijuana: #110513.
Dr. Holland recently edited and published “The
Pot Book,” which is a magnificent resource about marijuana. The book is
available in the MAPS store and proceeds directly fund MAPS’ medical marijuana
Since our last email newsletter, two more subjects have
enrolled in our ibogaine-outcome study, bringing us to a total of four subjects
out of an eventual 30. The study is following patients at Pangaea Biomedics, a
treatment facility in Playas de Tijuana, Mexico. Principal Investigator Valerie
Mojeiko and Co-Investigator Thomas Kingsley Brown, Ph.D., lead the study. The
researchers are collecting data from opiate-dependent subjects for one year after
ibogaine-assisted detoxification to evaluate the long-term outcomes of ibogaine
treatment. Brown is administering the Addiction Severity Index (ASI), our
primary outcome variable, on a monthly basis for a year.
On Nov. 3, 2010, the International
Journal of Drug Policy published online a paper about the ayahuasca track
during the Psychedelic Science in the 21st Century conference this
last April. Beatriz Caiuby Labate and Clancy Cavnar are the authors of the
expansion of the field of research on ayahuasca: Some reflections about the
ayahuasca track at the 2010 MAPS ‘Psychedelic Science in the 21st Century’
conference.” Labate is also author of Ayahuasca
Religions: A Biography and Critical Essays, which is published by MAPS and
available for purchase in the MAPS webstore.
If you are interested in communicating with Labate about her
paper or book, or reading the paper in full, you can contact her through her
website at www.bialabate.net.
MAPS recently published a very limited second
edition of David Jay Brown’s Mavericks of
the Mind. The book contains
new and expanded interviews with legendary thinkers, including Terence McKenna,
Allen Ginsberg, Timothy Leary, John Lilly, Carolyn Mary Kleefeld, Laura Huxley,
and Robert Anton Wilson. We expect to sell out of this book quickly.
Tickets: $10 each
or 12 for $100; Prize value: $800 - $1200
MAPS invites you to support psychedelic and marijuana
research by entering our ski-chalet vacation raffle. The winner will enjoy a
use of a lovely mountain house in Kirkwood (a ski resort 30 miles from South
Lake Tahoe, California).
The lucky raffle winner can choose to use the home for a ski
weekend or a 4-day midweek. The home is NOT available for the busiest holidays:
the week before Christmas, week of Christmas to New Years, Martin Luther King
weekend, Presidents Day weekend. Spring break is negotiable, depending upon the
The House is perched on the highest street in Kirkwood, high
above the bustle of condos and on a perfect sledding hill. It is a short walk
to the edge of the forest and ski area entrance, or a quick traverse onto the
runs without crossing a road. At the end of a day on the slopes the Kirkwood
shuttle vans drive back to the house.
This 1500 sq. foot house has two stories, three bedroom w/
two baths with a 12' x 20' deck and windows with views of Red Cliffs and the
ski area. Sleeping up to ten people in three bedrooms: the giant room has a
queen and 4 singles; another has a king and the third has a queen bed. The
kitchen is fully equipped with a stove, microwave, coffee maker, dishwasher
& refrigerator (there are no laundry machines or cable TV). There is a
large TV and video player, a CD/tape player and many comfy spots to enjoy your
time at 8,000 ft. The owners promise you a “Sweet and easy and quiet, a real
MAPS is hosting several events in downtown Los Angeles the
weekend of Dec. 10-12. From 6-11 p.m. Friday at Temple of Visions Gallery, MAPS
will host a free
reception, which will include an auction of art from nearly a dozen
internationally renowned visionary artists. On Saturday, Dec. 11, from 9 a.m- 6
p.m., at The Downtown Independent Theatre, MAPS will host Catalysts:
The Impact of Psychedelics from Consciousness to the Clinic (day one of
the mini-conference). When the conference ends for the day
at 6 p.m., doors will open at nearby Temple of Visions, where MAPS will host Critical Components, a dinner
benefitting our MDMA/PTSD study with veterans of war. When the benefit ends at
10 p.m., MAPS will host Flux, the official after party for the
Catalysts conference. The following Sunday, from 2-7 p.m., MAPS will host Catalysts:
The Impact of Psychedelics from Culture to Creativity (day two of the
mini-conference), also at Temple of Visions. Tickets
for these events are on sale now.